Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/ynwJkiYDnSc/251863.php
Wednesday 24 October 2012
In Atrial Fibrillation Patients On Rivaroxaban, More GI Bleeding Seen Than With Warfarin
Patients with atrial fibrillation (AF) experienced more major and non-major clinically relevant GI bleeding when taking rivaroxaban than patients taking warfarin. As part of the ROCKET AF trial, researchers from multiple institutions, including Harvard Medical School; Mount Sinai Medical Center; Janssen Research & Development; and Bayer HealthCare Pharmaceuticals, randomized 14,264 patients with nonvalvular AF to receive either rivaroxaban or dose-adjusted warfarin. Post-hoc analysis was performed on all patients while receiving study medication until 2 days after the last dose...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment